These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Characteristics of 1,3-bis-(2-ethoxycarbonylchromon-5-yloxy)-2-((S)- lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate, in absorption and excretion in rats and rabbits. Yoshimi A; Hashizume H; Kitagawa M; Nishimura K; Kakeya N J Pharmacobiodyn; 1992 Dec; 15(12):681-6. PubMed ID: 1296978 [TBL] [Abstract][Full Text] [Related]
26. Analytical evaluation of urinary excretion of furosemide in barrows. Ray AC; Tanksley TD; LaRue DC; Reagor JC Am J Vet Res; 1984 Jul; 45(7):1460-3. PubMed ID: 24049918 [TBL] [Abstract][Full Text] [Related]
27. Apparent intramolecular acyl migration and hydrolysis of furosemide glucuronide in aqueous solution. Sekikawa H; Yagi N; Lin ET; Benet LZ Biol Pharm Bull; 1995 Jan; 18(1):134-9. PubMed ID: 7735228 [TBL] [Abstract][Full Text] [Related]
29. High-performance liquid chromatography of chlorambucil prodrugs structurally related to lipids in rat plasma. Gonçalves JC; Razzouk C; Poupaert JH; Dumont P J Chromatogr; 1989 Sep; 494():389-96. PubMed ID: 2584338 [No Abstract] [Full Text] [Related]
30. A kinetic study on drug distribution: furosemide in rats. Kitani M; Ozaki Y; Katayama K; Kakemi M; Koizumi T Chem Pharm Bull (Tokyo); 1988 Mar; 36(3):1053-62. PubMed ID: 3409395 [No Abstract] [Full Text] [Related]
31. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Cao X; Gibbs ST; Fang L; Miller HA; Landowski CP; Shin HC; Lennernas H; Zhong Y; Amidon GL; Yu LX; Sun D Pharm Res; 2006 Aug; 23(8):1675-86. PubMed ID: 16841194 [TBL] [Abstract][Full Text] [Related]
32. Bioavailability and pharmacokinetics of furosemide marketed in Thailand. Kaojarern S; Poobrasert O; Utiswannakul A; Kositchaiwat U J Med Assoc Thai; 1990 Apr; 73(4):191-7. PubMed ID: 2394955 [TBL] [Abstract][Full Text] [Related]
33. Inclusion complexation of furosemide in cyclodextrins. Part 2: Implication on bioavailability. Ammar HO; Ghorab M; Emara LH; el-Nahhas SA; Makram TS Pharmazie; 1999 Mar; 54(3):207-10. PubMed ID: 10192107 [TBL] [Abstract][Full Text] [Related]
34. Variable furosemide absorption and poor predictability of response in elderly patients. Murray MD; Haag KM; Black PK; Hall SD; Brater DC Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769 [TBL] [Abstract][Full Text] [Related]
35. Bioavailability study of furosemide prodrugs in rats. Prandi C; Fagiolino P; Manta E; Dominguez Llera L Farmaco; 1992 Sep; 47(9):1225-34. PubMed ID: 1300128 [TBL] [Abstract][Full Text] [Related]
36. Development of absorption furosemide prodrugs: synthesis, in vitro and in vivo evaluation. Prandi C; Fagiolino P; Manta E; Llera LD; Aiache JM; Couquelet J Farmaco; 1992 Feb; 47(2):249-63. PubMed ID: 1510797 [TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate. Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406 [TBL] [Abstract][Full Text] [Related]